← Back to Screener
X4 Pharmaceuticals, Inc. Common Stock (XFOR)
Price$4.14
Favorite Metrics
Price vs S&P 500 (26W)26.44%
Price vs S&P 500 (4W)1.09%
Market Capitalization$381.86M
All Metrics
Book Value / Share (Quarterly)$2.05
P/TBV (Annual)2.06x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-5.19%
Cash Flow / Share (Quarterly)$-0.97
Price vs S&P 500 (YTD)5.61%
Gross Margin (TTM)83.60%
Net Profit Margin (TTM)-225.55%
EPS (TTM)$-4.38
10-Day Avg Trading Volume0.42M
EPS Excl Extra (TTM)$-4.38
Revenue Growth (5Y)58.59%
EPS (Annual)$-1.87
ROI (Annual)-30.16%
Gross Margin (Annual)83.60%
Net Profit Margin (5Y Avg)-5238.80%
Cash / Share (Quarterly)$2.78
Revenue Growth QoQ (YoY)79.08%
ROA (Last FY)-27.27%
Revenue Growth TTM (YoY)1273.21%
EBITD / Share (TTM)$-1.98
ROE (5Y Avg)-134.80%
Operating Margin (TTM)-247.44%
Cash Flow / Share (Annual)$-0.97
P/B Ratio2.05x
P/B Ratio (Quarterly)1.96x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)6.87x
Net Interest Coverage (TTM)-17.41x
ROA (TTM)-45.97%
EV / EBITDA (TTM)12.36x
EPS Incl Extra (Annual)$-1.87
Current Ratio (Annual)10.16x
Quick Ratio (Quarterly)9.88x
3-Month Avg Trading Volume0.56M
52-Week Price Return-29.59%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.95
P/S Ratio (Annual)10.88x
Asset Turnover (Annual)0.12x
52-Week High$6.84
Operating Margin (5Y Avg)-5090.25%
EPS Excl Extra (Annual)$-1.87
CapEx CAGR (5Y)17.14%
Tangible BV CAGR (5Y)-0.69%
26-Week Price Return30.42%
Quick Ratio (Annual)9.88x
13-Week Price Return11.03%
Total Debt / Equity (Annual)0.41x
Current Ratio (Quarterly)10.16x
Enterprise Value$241.105
Revenue / Share Growth (5Y)-10.81%
Asset Turnover (TTM)0.20x
Book Value / Share Growth (5Y)-14.43%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-225.44%
Cash / Share (Annual)$2.78
3-Month Return Std Dev83.75%
Net Income / Employee (TTM)$-1
ROE (Last FY)-42.51%
Net Interest Coverage (Annual)-17.41x
EPS Basic Excl Extra (Annual)$-1.87
Receivables Turnover (TTM)42.74x
Total Debt / Equity (Quarterly)0.41x
EPS Incl Extra (TTM)$-4.38
ROI (TTM)-54.75%
P/S Ratio (TTM)10.88x
Pretax Margin (5Y Avg)-5235.83%
Revenue / Share (Annual)$0.83
Tangible BV / Share (Annual)$1.95
Price vs S&P 500 (52W)-59.42%
Year-to-Date Return8.25%
5-Day Price Return6.39%
EPS Normalized (Annual)$-1.87
ROA (5Y Avg)-51.51%
Net Profit Margin (Annual)-225.55%
Month-to-Date Return4.84%
Cash Flow / Share (TTM)$-0.72
EBITD / Share (Annual)$-1.74
Operating Margin (Annual)-247.44%
LT Debt / Equity (Annual)0.41x
ROI (5Y Avg)-68.33%
LT Debt / Equity (Quarterly)0.41x
EPS Basic Excl Extra (TTM)$-4.38
P/TBV (Quarterly)2.06x
P/B Ratio (Annual)1.96x
Inventory Turnover (TTM)1.58x
Pretax Margin (TTM)-225.44%
Book Value / Share (Annual)$2.05
Price vs S&P 500 (13W)10.34%
Beta0.37x
Revenue / Share (TTM)$0.39
ROE (TTM)-115.27%
52-Week Low$1.35
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.20
4.20
4.22
4.33
Industry Peers — Biological Products(88)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
XFORX4 Pharmaceuticals, Inc. Common Stock | 10.88x | 1273.21% | 83.60% | — | $4.14 |
AMGNAmgen Inc | 5.13x | 9.95% | 73.30% | 2.93% | $349.39 |
GILDGilead Sciences Inc | 5.84x | 2.40% | 78.83% | 133.64% | $138.55 |
ARGXargenx SE American Depositary Shares | 12.46x | 89.56% | 150.91% | — | $828.35 |
BNTXBioNTech SE American Depositary Share | 8.75x | -11.81% | 84.21% | — | $102.12 |
BIIBBiogen Inc. Common Stock | 2.60x | 2.22% | 75.69% | -18.77% | $176.02 |
MRNAModerna, Inc. Common Stock | 11.02x | -39.93% | 70.32% | — | $54.68 |
NBIXNeurocrine Biosciences Inc | 4.49x | 21.45% | 98.18% | 2.31% | $128.41 |
EXELExelixis Inc | 4.96x | 6.85% | 96.39% | 31.10% | $44.38 |
TECHBio-Techne Corp. | 7.60x | 1.64% | 66.60% | -20.58% | $57.36 |
HALOHalozyme Therapeutics, Inc. | 5.74x | 37.55% | 83.62% | 22.89% | $66.64 |
About
X4 Pharmaceuticals develops therapies for rare immune system disorders. Its lead candidate mavorixafor is an oral, once-daily CXCR4 antagonist designed to increase white blood cell mobilization from the bone marrow. The company has two additional CXCR4-based candidates in preclinical development.